CNBC
US · 2 hrs ago
✦ 78◉ Centre
‘Buying stuff like it’s going out of fashion’: Biotech M&A on track for best year since pre-Covid
78Quality
0Ratings
0Comments
AI Analysis
Quality 78/100
Partisan intensity 25/100
ObjectivePartisan
◉ Centre ✓ Fair headline
Biotech mergers and acquisitions are experiencing a strong start in 2026, driven by patent expirations, improved market conditions, and pharmaceutical companies' efforts to strengthen their drug pipelines.
‘Buying stuff like it’s going out of fashion’: Biotech M&A on track for best year since pre-Covid
Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking in 2026 is off to a strong start.
Discussion 0 comments
Sort:
?
No comments yet — be the first to start the discussion!